The Evolving Context of Driver Mutations: ROS1 Rearrangement in Metastatic Non-Small Cell Lung Cancer

被引：0

作者：

DeCaire, Ximena ^{[1
]}

Streu, Erin ^{[1
]}

机构：

[1] CancerCare Manitoba, Winnipeg, MB, Canada

来源：

ONCOLOGY NURSING FORUM | 2016年 / 43卷 / 05期

关键词：

ambulatory care/office nursing; biotherapy/targeted therapies; clinical practice; lung cancer; CRIZOTINIB; ADENOCARCINOMA; FUSIONS;

D O I：

10.1188/16.ONF.544-547

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The discovery of driver mutations in non-small cell lung cancer (NSCLC) has led to the advent of targeted therapy and changed the clinical landscape. ROS1 is a rare driver mutation found in 1%-2% of patients diagnosed with NSCLC. This case highlights a young woman of Asian descent with no history of smoking diagnosed with NSCLC and ROS1 rearrangement and discusses the implications for oncology nurses in clinical practice.

引用

页码：544 / 547

页数：4

共 50 条

[1] Clinicopathological significance and diagnostic approach of ROS1 rearrangement in non-small cell lung cancer: a meta-analysis: ROS1 in non-small cell lung cancer
Yang, Jungho
Pyo, Jung-Soo
Kang, Guhyun
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2018, 33 (04): : 520 - 527
[2] Unusual presentation of ROS1 rearranged metastatic non-small cell lung cancer
Chen, Lanyi Nora
Keating, Claire
Leb, Jay
Saqi, Anjali
Shu, Catherine A.
RESPIRATORY MEDICINE CASE REPORTS, 2024, 51
[3] ROS1 gene rearrangement and copy number gain in non-small cell lung cancer
Jin, Yan
Sun, Ping-Li
Kim, Hyojin
Park, Eunhyang
Shim, Hyo Sup
Jheon, Sanghoon
Kim, Kwhanmien
Lee, Choon-Taek
Chung, Jin-Haeng
VIRCHOWS ARCHIV, 2015, 466 (01) : 45 - 52
[4] Progress of non-small-cell lung cancer with ROS1 rearrangement
Yang, Xin
Tang, Zhe
Li, Jing
Jiang, Jizong
Liu, Yue
FRONTIERS IN MOLECULAR BIOSCIENCES, 2023, 10
[5] Evaluation of a new diagnostic immunohistochemistry approach for ROS1 rearrangement in non-small cell lung cancer
Wang, Wenxian
Cheng, Guoping
Zhang, Gu
Song, Zhengbo
LUNG CANCER, 2020, 146 : 224 - 229
[6] Clinical characteristics of patients with ROS1 gene rearrangement in non-small cell lung cancer: a meta-analysis
Bi, Huanhuan
Ren, Dunqiang
Ding, Xiaoqian
Yin, Xiaojiao
Cui, Shichao
Guo, Caihong
Wang, Hongmei
TRANSLATIONAL CANCER RESEARCH, 2020, 9 (07) : 4383 - +
[7] Clinical significance of ROS1 5′ deletions in non-small cell lung cancer
Capizzi, Elisa
Dall'Olio, Filippo Gustavo
Gruppioni, Elisa
Sperandi, Francesca
Altimari, Annalisa
Giunchi, Francesca
Fiorentino, Michelangelo
Ardizzoni, Andrea
LUNG CANCER, 2019, 135 : 88 - 91
[8] Importance of ROS1 gene fusions in non-small cell lung cancer
Muminovic, Meri
Uribe, Carlos Rodrigo Carracedo
Alvarez-Pinzon, Andres
Shan, Khine
Raez, Luis E.
CANCER DRUG RESISTANCE, 2023, 6 (02) : 332 - 344
[9] Efficacy and safety of crizotinib in patients with ROS1 rearranged non-small cell lung cancer: a retrospective analysis
Masuda, Ken
Fujiwara, Yutaka
Shinno, Yuki
Mizuno, Takaaki
Sato, Jun
Morita, Ryo
Matsumoto, Yuji
Murakami, Shuji
Goto, Yasushi
Kanda, Shintaro
Horinouchi, Hidehito
Yamamoto, Noboru
Ohe, Yuichiro
JOURNAL OF THORACIC DISEASE, 2019, 11 (07) : 2965 - 2972
[10] CLINICAL ACTIVITY OF CRIZOTINIB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER HARBORING THE ROS1 GENE REARRANGEMENT
Ou, Sai-hong I.
Bang, Y-j
Camidge, D. R.
Engelman, J. A.
Clark, J. W.
Tye, L.
Wilner, Keith
Stephenson, P.
Chung, D. H.
Varella-Garcia, M.
Iafrate, A. J.
Shaw, A. T.
JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S455 - S455

← 1 2 3 4 5 →